The Patient Partnership Index is run by OVID Health the leading global agency in patient advocacy & engagement.

In 2020 we launched the Patient Partnership Index (PPI).

The PPI has since grown into a global initiative to enable patient groups, pharmaceutical and biotech companies to showcase, benchmark and evaluate the quality of their patient partnerships.

Its aim is to celebrate as many partnerships that meet the mark as possible, while sharing best practice and raising the bar across the industry. 

Now in its fifth year, the PPI evaluates and commends patient-pharmaceutical initiatives across communications, advocacy, clinical trials and market access.

“We are thrilled to reach this milestone of the fifth anniversary of the Patient Partnership Index, and as we celebrate this occasion, we look forward to recognizing even more outstanding collaborations that will continue to raise the bar across the industry. Over the years, we have witnessed remarkable partnerships that have significantly impacted patient care and advocacy.”

Jenny Ousbey, CEO & Founder, OVID Health

The Index is the culmination of thoughtful discussion and research, with a sole goal in mind: to improve patient outcomes through high quality patient-pharmaceutical partnerships in communications, advocacy, medical affairs and market access.

The concept of patient centricity is mainstream now in research and development, including in clinical trials and patient support programmes. But the Index looks beyond ‘centricity’ in R&D and into partnerships of equals for three reasons: one, because ‘centricity’ can be passive; two, it is traditionally tied to R&D; and three, because top quality communications between companies and patient groups is about collaborating as equals.

“As a relatively small company, entering the PPI was a way for us to show how we have been working closely with our charity partners and the communities they support, to deliver tangible projects that impact people’s lives.” 

Victoria Hayes, Director of Public Affairs, Northern Cluster at Kyowa Kirin, 2023 GOLD Standard entrant